ERBB2 and triple-negative breast carcinoma: In this single-center, real-world cohort, the overall pCR rate following neoadjuvant systemic therapy (NAST) was 36%, with the highest rates observed in HER2-positive and triple-negative breast cancer (TNBC) subtypes.